Navigation Links
New Vaccine To Be Used For First Time In Polio Outbreak Response

Eighteen new cases of polio have today been announced in Yemen, bringing the reported total number associated with an outbreak in the country to 22. Yemen had been polio-free since disease surveillance began in 1996 - a genetic investigation is ongoing to determine the precise origin of the outbreak. Experts fear that the number of cases will rise in the immediate future.

Teams of WHO and Ministry of Health epidemiologists and paediatricians remain on the ground, to investigate and control the outbreak and to intensify the planning for appropriate supplementary immunization activities.

Four cases of polio were confirmed on 20 April in just one governorate in the south-western part of the country, on the Red Sea coast. The latest 18 cases occurred across five governorates throughout Yemen, including in two districts in the country's capital Sanaa and suggesting the virus had spread across the country. Ongoing field investigations have identified additional suspected polio cases across the affected governorates in Yemen. Low immunization rates among Yemen's children may facilitate the spread of the virus.

Experts are now planning an outbreak response, using the recently-developed monovalent oral polio vaccine type 1(mOPV1). This new vaccine enables a precisely tailored immunological response to the type 1 poliovirus that is causing the outbreak. Compared to the commonly-used trivalent OPV, which offers protection against all three types of wild poliovirus, mOPV1 provides a greater immunity to type 1 wild poliovirus with fewer doses. Use of mOPV1 is expected during a nationwide immunization campaign in the second half of May. Yemen had already conducted a mass campaign on 11-14 April, as the country was considered to be at high-risk of polio re-infection from nearby Sudan where an outbreak of polio continues.

Experience in polio eradication demonstrates that outbreaks can be quickly contained with high quality immunization campaigns which reach every child under five years old.

Dedicated donor support and strong partnerships with the private sector have enabled the previous campaign in Yemen as well as swift development of the mOPV1 vaccine. However, a global funding gap of US$ 50 million must urgently be filled by July, to finance continued intensification of immunization campaigns in the second half of the year.

Global eradication efforts have reduced the number of polio cases from 350 000 annually in 1988 to 1267 cases in 2004. Six countries remain polio-endemic, with a further six where polio transmission is re-established. Concern is high that the ongoing outbreak of polio in Africa might lead to re-infection of more countries in the polio-free Horn of Africa and the Middle East. Yemen is the most recent of fifteen polio-free countries that have reported cases of polio since the epidemic began in late 2003.


'"/>

Source:WHO


Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. EuroVacc 02 HIV Vaccine Trial Begins
9. Active Vaccine Prevents Mice From Developing Prion Disease
10. Boosting The BCG Vaccine To Beat Tuberculosis
11. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
Breaking Biology News(10 mins):
(Date:3/28/2017)...  The National Pharmaceutical Council (NPC) today announced that ... organization as its newest member. David Cox , ... North America ), will serve as his company,s ... pleased to have Ipsen and Dr. Cox join NPC ... "We welcome their insights in helping us identify and ...
(Date:3/28/2017)... ... March 28, 2017 , ... LabKey and collaborator Just ... software solution, LabKey Biologics . Built in collaboration with Just and designed ... Biologics provides drug research teams tools for biological entity registration, assay data integration, ...
(Date:3/28/2017)... , March 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: ... to report compelling safety and clinical data from its phase ... 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for ... ... a complete safety profile at 6 months and showed no ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, ... proteomics analysis platform developed in the laboratory of Dr. James Heath at ...
Breaking Biology Technology: